Skip to main content
OpenTrials
Completed

NCT Number: NCT05824039

Safety and Efficacy of Medicinal Plant Extract in Overweight and Obese Participants.

The purpose of this randomized , double -blind clinical trial is to evaluate the efficacy and safety of a daily administration of Nitraria retusa extract in overweight and obese participants, during 10 days.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Faculty of Medicine of Sousse, 4000 Tunisia

Sousse, 4002, Tunisia

About this study

Medicinal plants are widely used for their accessibility, safety and effectiveness and may be an excellent alternative strategy for developing future drugs with minor adverse effects. Several studies concerning the potential of bioactive components in plants and food products and their link to many diseases including, diabetes, cardiovascular disease and obesity.

Nitraria retusa is a salt-tolerant plant that belongs to the Nitrariaceae family. It is particularly distributed in Asia, China, North Africa, Russia and Europe.It grows in the southern part of Tunisia and it is locally known as Ghardaq. The leaves serve as supplement for the tea and are used as poultice. Fresh leaves of Nitraria retusa have been used in traditional medicine in case of poisoning, upset stomach, ulcers, gastritis, enteritis, heartburn, colitis, and colonic abdominal pain.

Moreover, anticancer, antioxidant, antiviral and antimicrobial activities of N. retusa have been reported .Several reports evinced that the leaf of Nitraria retusa contains high amounts of tannins, alkaloids, steroids and flavonoids, which could be responsible for its beneficial effects . Previous studies have demonstrated the effect of Nitraria retusa extract in obese mice against high fat diet through lowering glucose and triglycerides and the enhancement of the lipid metabolism in liver.

The purpose of this study was to evaluate the efficacy and safety of short daily administration of Nitraria retusa extract in lipid profile in overweight and obese patients, during 10 days.

This study will be carried out in 2 departments: the laboratory of biophysics of the Faculty of Medicine of Sousse and Endocrinology and diabetology of CHU Farhat Hached Sousse ,Tunisia. At day 0 and day 10 all the population will benifit of biological assessment which include:

  • Biochimical parameters
  • Complete lipid profile (Total Cholesterol (T-C), High-density Lipoprotein (HDL) Low-density Lipoprotein (LDL) and Triglycerides( TG) .
  • Blood sugar
  • Liver Function Test : Alkaline phosphatase (ALP), gamma-glutamyltransferase (G-GT), albumin, Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), total ( TB) and direct bilirubin (DB).
  • Renal Function Test : Serum Creatinine, urea
  • Inflammatory assessment: Reactive protein C
  • Hematological parameters : (Red blood cells (RBC), White blood cell (WBC), Platelet, Hemoglobin and Hematocrit).

All Population will be randomized :Participant will be assigned to one of two treatments (low dose flavonoids or high dose flavonoids ). The diatry supplement :Nitraria retusa infusion will be prescribed at a quantity of powder which contained 5 mg of flavonoids or which contained 20 mg of flavonoids , added to 100 ml of boiling water and will be taken once a day at a bed time for 10 consecutive days.

Statistical analysis Data entry and analysis will be performed using SPSS 22.0 for Windows(IBM Corp., NY, USA ). Results will be considered significant at p < 0.05 Normal distributions of the data will be assessed by Shapiro-Wilk test. Within-group differences in the biological parameters before and after the intervention will be compared using paired t-test when data are normally distributed and Wilcoxon Signed Rank Test when data are not normaly distrubuted. Between-group differences (low dose vs high dose) in the parameters will be assessed by independent samples t-test (parametric and equal variances), Welch's t-test (unequal variances) and Mann-Whitney U test (nonparametric)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females
  • age range of 18 and 75 years
  • BMI >25 kg/ m^2

Exclusion criteria

  • Hypertension
  • Diabetes
  • Asthma
  • Smoking
  • Professional athletic
  • Pregnancy and breast feeding
  • Participant with medical or psychiatric disorder or chronic pathology,
  • Participant with eating disorder, food allergies.
  • Participant with a history of cardiovascular disease,
  • Participant with medication known to affect lipid metabolism,
  • Participant with major gastrointestinal problems.

Treatment and study plan

Tea infusion

Dietary Supplement

Tea infusion: The aerial parts of the medicinal plant were dried, then, they were powdered in a rotating knife grinder. The herbs were taken as tea infusion by the oral route. The powder was added to 100 ml of boiling water and the tea infusion was taken once time a day at the bed time and it was repeated for 10 days.

Primary outcomes

  1. Change in serum Triglycerides (TG) levels

    Time frame: 10 days

    To evaluate the efficacy of 20 mg of flavonoids in reducing serum TG compared with low dose group ( 5 mg of flavonoids) after 10 days administration .

  2. Change in serum High Density Lipoprotein Cholesterol (HDL-C) levels

    Time frame: 10 days

    To evaluate the efficacy of 20 mg of flavonoids in increasing HDL-C levels compared with low dose group ( 5 mg of flavonoids) after 10 days administration

  3. Change in Total Cholesterol ( TC) levels

    Time frame: 10 days

    To evaluate the efficacy of 20 mg of flavonoids in reducing TC levels compared with low dose group ( 5 mg of flavonoids) after 10 days administration.

  4. Change in Low Density Lipoprotein Cholesterol (LDL-C) levels

    Time frame: 10 days

    To evaluate the efficacy of 20 mg of flavonoids in reducing LDL-C levels compared with low dose group ( 5 mg of flavonoids) after 10 days administration

Secondary outcomes

  1. no change from baseline in Alkaline phosphatase levels

    Time frame: 10 days

  2. no change from baseline in Aspartate aminotransferase levels.

    Time frame: 10 days

  3. no change from baseline in Alanine aminotransferase levels.

    Time frame: 10 days

  4. no change from baseline in gamma-glutamyltransferase levels.

    Time frame: 10 days

  5. no change from baseline in Albumin levels .

    Time frame: 10 days

  6. no change from baseline in total bilirubin levels

    Time frame: 10 days

  7. no change from baseline in direct bilirubin levels

    Time frame: 10 days

  8. no change from baseline in urea levels

    Time frame: 10 days

  9. no change from baseline in creatinine levels

    Time frame: 10 days

  10. no change from baseline in fasting blood glucose levels

    Time frame: 10 days

  11. no change from baseline in Red blood cells levels

    Time frame: 10 days

  12. no change from baseline in White blood cells levels

    Time frame: 10 days

  13. no change from baseline in Hemoglobin levels

    Time frame: 10 days

  14. no change from baseline in Hematocrit levels

    Time frame: 10 days

  15. no change from baseline in Platelets levels

    Time frame: 10 days

  16. no change from baseline in Hemodynamic indicators: heart rate and blood pressure : systolic blood pressure and diastolic blood pressure

    Time frame: 10 days

  17. Adverse events

    Time frame: 10 days

    Adverse events reported

Sponsors and collaborators

Lead sponsor

Laouani Aicha

Other

Collaborators

  • Centre Hôpital Universitaire Farhat Hached
  • Faculty of Medicine, Sousse
  • University of Tsukuba
  • Université de Sousse

Registry information

Official study title

Safety and Efficacy of the Short Daily Administration of Nitraria Retusa Extract in Overweight and Obese Participants. .

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Apr 21, 2023
Registry last updated
Apr 25, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.